CBD And THC: Do They Complement Each Other Like Yin And Yang?

Full text links CiteDisplay options Display options Format AbstractPubMedPMID

Abstract

Increased public access to cannabis calls for a deeper understanding of cannabis's constituents and how they interact to induce clinical effects. Whereas trans-Δ9 -tetrahydrocannabinol (THC) is considered the main psychoactive component in cannabis, producing the associated "high" or "euphoria," various findings demonstrate medical potential for cannabidiol (CBD), from anxiolytic to antiepileptic implications. This has translated into a public optimism and given way to the popular opinion that CBD can provide countless other therapeutic benefits, including the potential to mitigate some of the adverse side effects of THC, such as intoxication, psychomotor impairment, anxiety, and psychotic symptoms. This is particularly relevant for patients seeking to garner therapeutic benefits from cannabis without experiencing the burden of a significant subjective high. Thus, this article analyzes the scientific evidence available to support or disprove the idea that presence of CBD is beneficial and can exude a protective effect against THC. A thorough review of relevant literature, a basis from which to interpret such evidence through a critical mechanistic discussion, and the implications for patients are presented in this article.

Keywords: cannabidiol; cannabinoids; cannabis; intoxication; marijuana; medical marijuana; psychosis; subjective effects; trans-δ9-tetrahydrocannabinol.

© 2020 Pharmacotherapy Publications, Inc.

PubMed Disclaimer

References

1. 1. Elsohly MA, Gul W, Wanas AS, Radwan MM. Synthetic cannabinoids: analysis and metabolites. Life Sci 2014;1:78-90.
2. 1. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;10:515-27.
3. 1. Di Forti M, Morgan C, Dazzan P, et al. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;6:488-91.
4. 1. Freeman TP, Morgan CJ, Hindocha C, Schafer G, Das RK, Curran HV. Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints? Addiction 2014;10:1686-94.
5. 1. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 2017;21:2011-20.

Show all 73 references

Publication types

• Research Support, Non-U.S. Gov't Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Review Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

MeSH terms

• Cannabidiol / pharmacokinetics* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Dronabinol / pharmacokinetics* Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Drug Synergism Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Humans Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

Substances

• Cannabidiol Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search
• Dronabinol Actions
  • Search in PubMed
  • Search in MeSH
  • Add to Search

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley